Basit öğe kaydını göster

dc.contributor.authorTopcu, Turkan Ozturk
dc.contributor.authorInal, Ali
dc.contributor.authorKodaz, Hilmi
dc.contributor.authorOdabas, Hatice
dc.contributor.authorDuran, Ayse Ocak
dc.contributor.authorŞEKER, MEHMET METİN
dc.contributor.authorInanc, Mevlide
dc.contributor.authorELKIRAN, EMİN TAMER
dc.contributor.authorGunaydin, Yusuf
dc.contributor.authorMenekse, Serkan
dc.contributor.authorUrakci, Zuhat
dc.contributor.authorBİLİCİ, Mehmet
dc.contributor.authorCihan, Sener
dc.contributor.authorGeredeli, Caglayan
dc.contributor.authorSEZER, EMEL
dc.contributor.authorUncu, Dogan
dc.contributor.authorArpaci, Erkan
dc.contributor.authorOzturk, Banu
dc.contributor.authorBal, Oznur
dc.contributor.authorUYSAL, MÜKREMİN
dc.contributor.authorTANRIVERDİ, ÖZGÜR
dc.contributor.authorGumus, Mahmut
dc.contributor.authorUstaalioglu, Bala Basak Oven
dc.contributor.authorSuner, Ali
dc.contributor.authorCokmert, Suna
dc.contributor.authorHacibekiroglu, Ilhan
dc.contributor.authorAydin, Kubra
dc.contributor.authorIsikdogan, Abdurrahman
dc.contributor.authorTastekin, Didem
dc.date.accessioned2021-03-04T07:56:46Z
dc.date.available2021-03-04T07:56:46Z
dc.date.issued2018
dc.identifier.citationInal A., Kodaz H., Odabas H., Duran A. O. , ŞEKER M. M. , Inanc M., ELKIRAN E. T. , Gunaydin Y., Menekse S., Topcu T. O. , et al., "Prognostic factors of patients who received chemotherapy after cranial irradiation for non-small cell lung cancer with brain metastases: A retrospective analysis of multicenter study (Anatolian Society of Medical Oncology)", JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, cilt.14, sa.3, ss.578-582, 2018
dc.identifier.issn0973-1482
dc.identifier.otherav_60b401f8-7f6c-49fe-9a2c-4a5b389b93b9
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/67460
dc.identifier.urihttps://doi.org/10.4103/0973-1482.176417
dc.description.abstractPurpose: Almost half of all patients diagnosed with non-small cell lung cancer (NSCLC) have distant metastases at presentation. One-third of patients with NSCLC will have brain metastases. Without effective treatment, the median survival is only 1 month. However, it is difficult to treat brain metastases with systemic chemotherapy since the agents have difficulty crossing the blood-brain barrier. Therefore, it is important to estimate the patient's survival prognosis. The aim of this study was to analyze prognostic factors for survival in Turkish patients who received chemotherapy after cranial irradiation for NSCLC with brain metastases.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectKlinik Tıp
dc.subjectOnkoloji
dc.subjectİç Hastalıkları
dc.subjectKlinik Tıp (MED)
dc.subjectONKOLOJİ
dc.subjectTıp
dc.titlePrognostic factors of patients who received chemotherapy after cranial irradiation for non-small cell lung cancer with brain metastases: A retrospective analysis of multicenter study (Anatolian Society of Medical Oncology)
dc.typeMakale
dc.relation.journalJOURNAL OF CANCER RESEARCH AND THERAPEUTICS
dc.contributor.departmentMersin State Hospital , ,
dc.identifier.volume14
dc.identifier.issue3
dc.identifier.startpage578
dc.identifier.endpage582
dc.contributor.firstauthorID252728


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster